Belgian biopharmaceutical group UCB said on Friday it will acquire U.S.-based Neurona Therapeutics for up to $1.15 billion in a deal aimed at strengthening its epilepsy portfolio.
UCB will pay $650 million upfront, along with up to $500 million in potential milestone payments for the privately held Neurona, the company said.
Read Also – Alamar Biosciences hits $1.5 billion valuation as shares surge in Nasdaq debut
Neurona is a clinical-stage biotherapeutics company backed by investors including Fidelity and Schroders Capital, among others.
The deal is expected to close by the end of the second quarter of 2026.
Meanwhile, UCB said its 2026 revenue guidance remains unchanged, but it now anticipates annual adjusted EBITDA to grow in the high single-digit to mid-teens percentage range.
